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Abstract
BCL-2-related ovarian killer (BOK) is a conserved and widely expressed BCL-2 family member with sequence homology to
pro-apoptotic BAX and BAK, but with poorly understood pathophysiological function. Since several members of the BCL-2
family are critically involved in the regulation of hepatocellular apoptosis and carcinogenesis we aimed to establish whether
loss of BOK affects diethylnitrosamine (DEN)-induced hepatocarcinogenesis in mice. Short-term exposure to DEN lead to
upregulation of BOK mRNA and protein in the liver. Of note, induction of CHOP and the pro-apoptotic BH3-only proteins
PUMA and BIM by DEN was strongly reduced in the absence of BOK. Accordingly, Bok-/- mice were signiﬁcantly
protected from DEN-induced acute hepatocellular apoptosis and associated inﬂammation. As a consequence, Bok-/- animals
were partially protected against chemical-induced hepatocarcinogenesis showing fewer and, surprisingly, also smaller
tumors than WT controls. Gene expression proﬁling revealed that downregulation of BOK results in upregulation of genes
involved in cell cycle arrest. Bok-/- hepatocellular carcinoma (HCC) displayed higher expression levels of the cyclin kinase
inhibitors p19INK4d and p21cip1. Accordingly, hepatocellular carcinoma in Bok-/- animals, BOK-deﬁcient human HCC cell
lines, as well as non-transformed cells, showed signiﬁcantly less proliferation than BOK-proﬁcient controls. We conclude
that BOK is induced by DEN, contributes to DEN-induced hepatocellular apoptosis and resulting hepatocarcinogenesis. In
line with its previously reported predominant localization at the endoplasmic reticulum, our ﬁndings support a role of BOK
that links the cell cycle and cell death machineries upstream of mitochondrial damage.
Introduction
Hepatocellular carcinoma (HCC) is the most frequent liver
cancer and among the most lethal and prevalent malig-
nancies in humans [1]. Several risk factors are associated
with the development of HCC. These include chronic
infections with hepatitis viruses (HBV or HCV), exposure
to aﬂatoxin-B1, polycystic aromatic hydrocarbons and
nitrosamines, as well as alcoholic and non-alcoholic fatty
liver disease [2]. HCC can be triggered in experimental
animal models with a single postnatal injection of the
chemical carcinogen diethylnitrosamine (DEN) [3]. The
intense inﬂammatory response triggered by the hepatic
injury leads to the immune surveillance of the damaged
tissue [4]. However, this response also further stimulates
tumor development via compensatory hepatocyte pro-
liferation [5, 6]. Apoptotic cell death is recognized as a
crucial event in chemical-induced hepatocyte cell death and
HCC development [7]. Several BCL-2 family members
have been implicated in hepatocarcinogenesis and in cou-
pling apoptosis regulation and cell proliferation in unique
ways [8, 9].
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BCL-2-related ovarian killer (BOK) is a BCL-2 family
member with a function difﬁcult to elucidate [10]. Early
studies proposed that BOK may act as a BAX-like protein,
based on sequence homology and since its over-expression
induced cell death [11, 12]. To date, functional studies on
mammalian forms of BOK have largely been restricted to
over-expression systems. Interestingly, and in contrast to
BAX and BAK, BOK localizes preferentially to the mem-
branes of the endoplasmic reticulum (ER) and the Golgi
apparatus, but only weakly to mitochondria. Furthermore,
we and others [13, 14] have shown that signiﬁcant amounts
of BOK are also present in the nucleus of mouse and human
cells, including primary mouse hepatocytes and mouse
embryo ﬁbroblasts [15], as well as human non-small cell
lung cancer cells [16]. ER-localization of BOK is supported
by its interaction with inositol-3-phosphate receptors (IP3R)
[17] and by its effect on Ca2+ homeostasis in neurons [18].
BOK was recently described to be rapidly turned over by
the ubiquitin/proteasome pathway [19, 20] and to act as a
non-canonical effector of intrinsic apoptosis regulated by
Fig. 1 BOK contributes to DEN-induced liver damage. a Bok mRNA
expression in the livers of WT and Bok-/- animals after DEN exposure.
Hprt served as reference gene. Values represent the mean± SD (n= 3
mice per group). b Serum ALT levels were determined in WT and
Bok-/- mice after DEN exposure (100 mg/kg BW). Values represent
mean± SD. c Representative ﬂuorescence micrographs of TUNEL
staining and d quantiﬁcation of TUNEL-positive cells in livers from
WT and Bok-/- animals treated with DEN (100mg/kg BW). Values
represent the mean± SD (n= 3 mice per group). e Quantitative western
blot analysis using near-infrared ﬂuorescence of activated caspase-3 in
liver lysates from WT and Bok-/- animals 3 days after DEN (100mg/kg)
injection. Values represent the mean± SD (n= 3 mice per group)
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ER-associated degradation [19]. Whereas no overt sponta-
neous phenotype was seen in three independently derived
Bok-deﬁcient mouse strains [19, 21, 22], indirect indication
for a physiological pro-apoptotic role of BOK was derived
from analysis of Bok-/-Bax-/- females, which have an
abnormally increased number of oocytes [23] and from a
further, modest increase in lymphocyte numbers in a Bax-/-
Bak-/- hematopoietic system upon additional loss of Bok [24,
25]. Interestingly, BOK was identiﬁed in a genomic region
that is relatively frequently deleted in human cancers [26].
Loss of Bok did, however, not affect the outcome of Eµ-myc
transgene-induced preB-/B-cell lymphoma in the mouse
[21]. The same study also showed that endogenous BOK
levels are very low in lymphocytes, whereas generally BOK
is widely expressed, with readily detectable protein
expression levels in most tissues, particularly in reproduc-
tive organs, brain, and gastrointestinal tract, including liver
[15, 21]. Of note, there is no indication for increased
deletion of the BOK gene in human HCC according to The
Cancer Genome Atlas (TCGA) database. Overall, the
pathophysiological role of BOK remains elusive.
Here, we show that DEN treatment of mice results in an
increased BOK expression in the liver and that BOK con-
tributes to DEN-induced acute hepatocellular apoptosis.
Induction of CHOP, PUMA, and BIM by DEN was
decreased in Bok-/- mice, as was the oligomerization of
BAX, supporting a pro-apoptotic role of BOK upstream of
mitochondria. As a consequence of reduced liver damage
and resulting compensatory proliferation in an inﬂammatory
environment, the incidence of HCC was signiﬁcantly
reduced in Bok-/- mice compared to WT controls. Surpris-
ingly, loss of BOK also resulted in smaller tumors, which
correlated with reduced cellular proliferation of HCC both
in vivo and in vitro, indicating that BOK does not only
contribute to initial hepatocyte cell death but also affects
cell cycle progression during hepatocarcinogenesis. Alto-
gether, these data show that BOK plays a previously
unrecognized role in the pathogenesis of liver disease.
Results
BOK contributes to chemical-induced acute liver
damage and hepatocyte apoptosis
DEN is a potent alkylating agent inducing DNA damage
and hepatocellular cell death upon conversion into alkyl-
diazohydroxide by intrahepatocellular cytochrome P450
[27]. In order to evaluate if DEN affects BOK expression
levels we treated adult WT animals with DEN (100 mg/kg
BW). We observed that DEN promoted a strong upregula-
tion (16-fold and 19-fold after 1 and 3 days, respectively) of
Bok mRNA in WT livers (Fig. 1a), indicating that Bok was
transcriptionally induced. Bok induction was at least par-
tially dependent on c-Jun N-terminal kinase (JNK) as it was
signiﬁcantly reduced by D-JNKI1 inhibitor at early time
points (1 day), whereas Bok levels were not affected upon
loss of p53 (Supplementary Fig. S1). Importantly, BOK
protein levels were also signiﬁcantly increased after DEN
challenge compared to controls (Fig. 2a). To test a potential
pro-apoptotic role of BOK we compared DEN-induced
acute liver damage in WT and Bok-/- animals. As shown in
Fig. 1b, serum ALT levels were lower in Bok-/- animals
1 day after DEN exposure when compared to WT controls.
TUNEL staining revealed less hepatocyte cell death in
Bok-/- mice (Fig. 1c and d). Proteolytic processing of
procaspase-3 into its active form was detected in livers from
treated WT mice but was reduced in Bok-/- mice (Fig. 1e)
indicating that Bok-/- animals were partially protected
against DEN-induced liver damage. Of note, CHOP and the
pro-apoptotic BH3-only proteins PUMA and BIM were
strongly induced by DEN in WT livers, but clearly less so in
livers of Bok-/- mice (Fig. 2b and c and Supplementary
Fig. S2a). Taken together, these data indicate that DEN
treatment induces BOK expression and that BOK con-
tributes to DEN-mediated hepatocellular apoptosis upstream
of CHOP, PUMA, and BIM. In support of a pro-apoptotic
role of BOK upstream of mitochondrial permeabilization,
we detected less activated BAX, as assessed by its oligo-
merization status, in livers from DEN-treated Bok-/- mice
compared to WT controls (Supplementary Fig. S2b).
Bok-/- mice are partially protected from chemical-
induced hepatocarcinogenesis
DEN is a widely accepted agent to induce hepatocarcino-
mas in mice [3]. Acute cell death triggered by DEN pro-
motes an inﬂammatory response that further stimulates
tumor development [5]. We observed that Bok-/- animals
presented signiﬁcantly reduced mRNA levels of the pro-
inﬂammatory cytokines TNFα and IL-6 in their livers
compared to WT controls after short-term exposure to DEN,
and that leukocyte inﬁltration, which became evident at day
3 of treatment, seemed to correlate with the degree of liver
damage (Supplementary Fig. S3). We also noted that
hepatocyte proliferation was decreased in Bok-/- livers
compared to WT controls 10 days after DEN treatment
(Supplementary Fig. S4). Considering this, we sought to
investigate how loss of BOK would affect DEN-induced
hepatocarcinogenesis. Fifteen-day-old male WT and Bok-/-
mice were injected with a single dose of DEN (25 mg/kg
BW; a dose that also induced BOK and BOK-dependent
liver damage in adult WT mice, see Supplementary
Fig. S5). At the endpoint of 9 months, macroscopic tumor
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development was observed in both genotypes (Fig. 3a).
However, Bok-/- animals presented signiﬁcantly (three
times) fewer tumors than WT controls (Fig. 3b). Interest-
ingly, a reduced average tumor size was also observed in
Bok-/- animals (Fig. 3c). Blinded histopathological evalua-
tion conﬁrmed that the prevalence of histologically con-
ﬁrmed HCC is signiﬁcantly reduced in Bok-/- mice (Fig. 3d)
and that Bok-/- animals present a lower incidence of
inﬂammation, ballooning and steatohepatitis, and less
steatosis (Fig. 3e and f). Neither WT nor Bok-/- tumors or
surrounding liver tissue showed increased signs of ﬁbrosis
(Supplementary Fig. S6). Taken together, these data indi-
cate that BOK contributes to chemical-induced
hepatocarcinogenesis.
Fig. 2 BOK protein is increased in response to DEN and promotes
induction of CHOP, BIM and PUMA. a Quantitative western blot
analysis showing increase in BOK protein levels in WT animals
treated with DEN (100 mg/kg). Lower band of BOK is due to alter-
native START codon [20]. Values represent mean± SD (n= 3–6 per
group). Statistical analysis was performed by one-way ANOVA fol-
lowed by a Tukey post-test analysis. b Induction of Bim and Puma
mRNA by DEN (100 mg/kg) is decreased in livers of Bok-/- mice.
Gapdh served as reference gene. Values are normalized to PBS con-
trols and represent the mean± SD (n= 3 mice per group). c Repre-
sentative western blot data of liver lysates from DEN (100 mg/kg)
treated WT and Bok-/- mice and quantiﬁcation using near-infrared
ﬂuorescence. Values represent the mean± SD (n= 6 mice per group)
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BOK deﬁciency limits cell proliferation
Some BCL-2 family members are known to inﬂuence cell
proliferation in addition to cell survival [28]. Bok-/- animals
presented not only fewer, but also smaller tumors than WT
controls. Considering this, we compared the proliferative
rate in liver tumors from WT and Bok-/- animals 9 months
after DEN treatment. Immunohistochemical quantiﬁcation
of the proliferation marker Ki-67 showed that tumors from
Bok-/- animals presented three times fewer Ki-67 positive
cells than tumors from WT controls (Fig. 4a and b). To
evaluate if BOK deﬁciency could directly affect cell pro-
liferation in vitro, we compared proliferation rates of
immortalized human hepatocytes (IHH) and human HCC
Fig. 3 BOK promotes chemical-induced hepatocarcinogenesis. a
Gross liver tumor morphology and corresponding representative H&E-
stained tumors in WT and Bok-/- animals 9 months after DEN treatment
(25 mg/kg BW). b Quantiﬁcation of liver tumors in WT and Bok-/-
animals. Values represent the mean± SD (WT n= 10; Bok-/- n= 13).
c Average tumor size per group (diameter by caliper). d Quantiﬁcation
of histologically conﬁrmed HCC. Values represent the mean± SD (n
= 10 per group; blindly evaluated and randomly selected). e H&E-
stained sections of livers 9 months after DEN injection. Histopatho-
logical examination revealed that Bok-/- animals are less prone to
inﬂammation, ballooning, and steatohepatitis and f show less steatosis
in non-tumor areas. Values represent the mean± SD (n= 10 per
group; blindly evaluated and randomly selected)
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Fig. 4 Loss of BOK affects cellular proliferation. a Immunohistochemistry showing Ki-67 staining in HCC tumors from WT and Bok-/- animals. b
Quantiﬁcation of Ki-67 positive cells in HCC tumors from WT and Bok-/- mice. Values represent the mean± SD (n= 3 mice per group). c Growth
curves and colony formation assay of IHH subclones with CRISPR/Cas9-mediated gene disruption of BOK. d Growth curves and colony
formation assay of SV40 MEF derived from three different WT and Bok-/- embryos, each. Stable re-expression of BOK in Bok-/- SV40 MEF
rescues the growth defect. e Stable re-expression of a BOK mutant, BOK(AAA), in which the predicted NES sequence within the BH3 domain has
been mutated (L72A,R73A,L74A), fails to rescue the growth defect in Bok-/- SV40 MEF. Values represent the mean± SD (n= 3). f BOK(AAA)
accumulates in the cytoplasm compared to wildtype BOK. T total, C cytoplasmic fraction, N nuclear fraction. *p< 0.05, **p< 0.01, ***p< 0.005,
****p< 0.001
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Fig. 5 Loss of BOK induces p19INK4d and p21cip1 expression. a
Quantitative western blot analysis of p19INK4d expression using near-
infrared ﬂuorescence of liver extracts from WT and Bok-/- animals
treated with DEN (100 mg/kg BW). Values represent the mean± SD
(n= 4 mice per group). b Immunohistochemistry of liver sections
showing cytoplasmic and nuclear localization of p19INK4d in untreated
WT animals and predominantly nuclear localization in Bok-/- livers. c
Immunohistochemistry of liver sections indicating p19INK4d staining
(red) in tumors from WT and Bok-/- animals. Counterstain was per-
formed with Mayer’s Hematoxilin. d Quantitative western blot analysis
using near-infrared ﬂuorescence of p21cip1 expression of liver extracts
from WT and Bok-/- animals treated with DEN (100 mg/kg BW).
Values represent the mean± SD (n= 4 mice per group). e Immuno-
histochemistry of liver sections showing negative staining for p21cip1
in untreated WT animals and predominantly nuclear localization in
Bok-/- mice (red). f Immunohistochemistry of liver sections indicating
p21cip1 negative staining in tumors from WT mice and positive
staining for Bok-/- tumors (red). T tumor area, NT non-tumor area. At
least two tumors/animal and 3–4 animals per genotype were used for
quantiﬁcations in (c) and (f)
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cell lines upon downregulation of BOK. As shown in
Fig. 4c (and Supplementary Fig. S7), IHH cells and HepG2
human hepatocarcinoma cells with CRISPR/Cas9-mediated
BOK disruption, or the HCC cell line HLE upon shRNA-
mediated BOK downregulation, proliferated signiﬁcantly
slower than controls. Growth curves and colony formation
assays of immortalized mouse embryo ﬁbroblasts (SV40
MEF) isolated from WT and Bok-/- mice further conﬁrmed
that loss of BOK can result in signiﬁcantly slower pro-
liferation (Fig. 4d). Importantly, re-expression of BOK in
Bok-/- MEF fully rescued this proliferation defect, proving
that it is a BOK-speciﬁc effect (Fig. 4d). However, re-
expression of a BOK mutant, BOK(L72A,R73A,L74A), in
which the reported nuclear export signal (NES) [13] was
destroyed, failed to rescue the growth defect in Bok-/- MEF
(Fig. 4e). The same mutant also showed a reduced locali-
zation in puriﬁed nuclear fractions and consequently accu-
mulated in the cytoplasm (Fig. 4f). Given that the NES of
BOK is situated within its BH3-domain, these data imply
that BOK requires either its BH3 domain and/or a nuclear
localization to drive proliferation. Nuclear localization of
BOK was conﬁrmed in HLE cells and, interestingly,
cytoplasmic-to-nuclear ratio of BOK likewise increased
upon knockdown of BOK (Supplementary Fig. S7g). Loss
of BOK also negatively affected cell growth of non-
transformed bone marrow-derived mast cells (Supplemen-
tary Fig. S8). Taken together, these data indicate that BOK
plays a role in controlling cellular proliferation in vitro and
in vivo.
Loss of BOK promotes induction of cyclin kinase
inhibitors p19ink4d and p21cip1
To gain further insight into the role of BOK in cell pro-
liferation, expression proﬁling of 88 cell cycle related
genes was performed with IHH and two human HCC lines,
in which BOK was deleted or downregulated. Only few
genes showed consistent changes in expression levels
among the three different cell lines. The genes upregulated
in BOK-deﬁcient cells were linked to cell cycle arrest and
DNA damage response, including cyclin kinase inhibitor
CDKN2D (p19INK4d), BCL-2, TP53, RPA3, GADD45A-6,
CDK5, whereas only CCNA2, encoding for cyclin A2, was
consistently downregulated (Supplementary Fig. S9). To
better understand the impact of BOK deletion on CDKN2D
expression, we evaluated p19INK4d protein expression in
livers from short-term DEN treated WT and Bok-/- animals.
Of note, p19INK4d steady-state protein levels were, on
average, two times higher in livers from Bok-/- animals
compared to WT controls (Fig. 5a). Whereas p19INK4d
levels increased upon DEN treatment in WT livers, they
remained unchanged in Bok-/- livers. Interestingly,
p19INK4d was differentially distributed in hepatocytes of
WT and Bok-/- animals. Whereas p19INK4d was localized
both in the cytoplasm and in the nucleus of WT hepato-
cytes, it was found predominantly in the nucleus of Bok-/-
hepatocytes (Fig. 5b). In the tumors of DEN-treated WT
animals p19INK4d expression was reduced compared to
adjacent ‘healthy’ liver tissue, whereas the tumors of Bok-/-
animals expressed readily detectable levels of p19INK4d in
both HCC tumors and surrounding ‘healthy’ liver tissue
(Fig. 5c). We also observed that BOK repression affected
expression of another cyclin kinase inhibitor, p21cip1
(Fig. 5d). p21cip1 was strongly expressed and mainly
localized in the nuclei of hepatocytes from Bok-/- mice,
while it was hardly detectable in WT hepatocytes (Fig. 5e).
In addition, tumors and adjacent tissue from Bok-/- animals
were positive for p21cip1, whereas tumors from WT ani-
mals were consistently negative (Fig. 5f). Using isogenic
HCT-116 colorectal carcinoma cells proﬁcient or deﬁcient
for p53 or p21, respectively, we observed that the growth
defect inﬂicted upon downregulation of BOK was depen-
dent on p21 and p53 (Supplementary Fig. S10). Taken
together, these data indicate that BOK depletion affects the
expression of genes implicated in cell cycle arrest, and
remarkably, impacts on the expression pattern of p19INK4d
and p21cip1 in hepatocytes and HCC cells.
Fig. 6 Schematic model of how BOK contributes to DEN-induced
HCC. BOK levels in the liver are increased in the short-term
response to DEN and BOK contributes to liver damage upstream of
BIM and PUMA induction. As a consequence of reduced cell death,
associated inﬂammation and compensatory proliferation, Bok-/- mice
develop fewer HCC tumors in the long term. Additionally, BOK has a
likely cell death-independent function of positively modulating
cellular proliferation of HCC cells, resulting in smaller tumors in
Bok-/- mice
T. Rabachini et al.
Discussion
Despite its discovery 20 years ago the physiological and
pathophysiological relevance of BOK remains largely
unknown. BOK induces apoptosis when over-expressed and
it shows best amino acid sequence homology to BAK and
BAK. However, it is currently controversially discussed
whether BOK is a genuine pro-apoptotic BCL-2 family
member and whether it can induce intrinsic apoptosis
independently of BAX/BAK [15, 18, 19, 22, 29–31]. What
has emerged is that BOK is widely expressed and readily
detectable at the endogenous protein level in most cell
types, maybe with the exception of the hematopoietic sys-
tem [21], and that in contrast to BAX and BAK, most of the
cytoplasmic BOK localizes to the ER; furthermore, BOK is
also prominently found in nuclear fractions [13–16].
BOK is consistently expressed throughout the gastro-
intestinal tract, with high levels in the liver [21]. Here we
show that BOK is strongly induced at the mRNA and
protein levels upon short-term treatment with DEN and,
importantly, that BOK promotes DEN-induced liver
damage and associated inﬂammation. Induction of Bok
mRNA seems to be at least partially mediated by JNK, but
independent of p53, which is in analogy to a report for the
induction of Puma by DEN [8]. As shown by Das and
colleagues using conditional Jnk1/2-deﬁcient mice, the role
of JNK is ambiguous, with different effects on HCC
development in hepatocytes or non-parenchymal cells [32].
Our study was performed in a constitutive Bok-deﬁcient
strain, which limits the conclusions to some extents. Con-
ditional deletion of Bok (i.e. hepatocyte-speciﬁc and/or
nonparenchymal-speciﬁc deletion) will be necessary to
demonstrate the contribution of BOK in hepatocytes or non-
parenchymal cells, respectively, in the DEN model and,
importantly, to address a possible role of liver resident (or
recruited) leukocytes therein.
Our ﬁndings show that BOK contributes to chemical-
induced hepatocellular apoptosis (see Fig. 6 for a schematic
model). In line with its localization at the ER and our pre-
vious observation that over-expressed BOK induces BIM
and PUMA [15], we found that BOK acts upstream of
CHOP, BIM, and PUMA induction in response to DEN. A
connection between BOK and CHOP has been reported
earlier, albeit in a different context [22]. Overall, these data
support a pro-apoptotic role of BOK upstream of mito-
chondrial apoptotic events mediated by BAX/BAK, and this
was further underlined by our ﬁnding that BAX oligomer-
ization, which we used as a readout for its activation status,
is reduced in livers of short-term DEN-treated Bok-/- mice
compared to WT controls.
Reduction of apoptosis and, consequently, inﬂammation
and compensatory hepatocellular proliferation is strongly
associated with reduced HCC development [5–7]. In line
with these observations, we report that at the endpoint of
9 months after DEN exposure Bok-/- animals were partially
protected from HCC development, displaying signiﬁcantly
reduced tumor numbers, as well as smaller tumors. Inter-
estingly, BOK was identiﬁed in a genomic region that
undergoes relative frequent deletion in human cancers,
making BOK one of the most often deleted members among
the pro-apoptotic BCL-2 family [26]. However, according
to The Cancer Genome Atlas (TCGA) database, the human
BOK locus is rarely deleted in primary liver cancer. Like-
wise, BOK mRNA levels do not seem to be decreased in
human HCC based on publicly available databases. Infor-
mation on the BOK protein status in human HCC speci-
mens is currently missing. Nevertheless, we observed that
established HCC in WT mice expressed comparable levels
of BOK protein compared to healthy liver (data not shown).
This apparent lack of selection pressure to lose BOK during
liver cancerogenesis is in line with our ﬁnding that BOK
promotes HCC. Our ﬁndings support other reports on pro-
apoptotic BCL-2 proteins promoting HCC, such as PUMA
[8] or BID [9]. Inversely, loss of anti-apoptotic MCL-1 in
hepatocytes was shown to trigger spontaneous apoptosis
and to promote development of HCC [33]. Along the same
line, over-expression of BCL-2 was shown to inhibit SV40
large T antigen transgene-induced liver cancer development
[34]. Interestingly, loss of Puma has also been implicated
with decreased tumorigenesis in a radiation-induced thymic
lymphoma model [35, 36]. Collectively, these ﬁndings
suggest that damage-induced cell death can promote tumour
development by causing enhanced proliferation of pro-
genitor cells, which due to their rapid proliferation may
sustain oncogenic DNA lesions.
Following our observation that Bok-/- mice also presented
smaller tumors, we demonstrate that loss of BOK negatively
affects cellular proliferation. Tumors from Bok-/- animals
proliferated slower than tumors form WT mice. In addition,
two human HCC lines, IHH, MEF, and non-transformed
mast cells proliferated signiﬁcantly slower upon loss of
BOK. This result points towards an important role of BOK
that may be independent of its role in cell death regulation.
Based on these ﬁndings that link BOK to the regulation of
HCC proliferation, targeting BOK in established HCC
expressing high levels of BOK may be beneﬁcial in slowing
tumor growth.
A nuclear localization of BOK has been reported by
several groups and linked to proliferation in trophoblasts
during early placentation [13, 14]. In support of this, we
have previously shown that signiﬁcant amounts of total
BOK are found in puriﬁed nuclear fractions of MEF, mouse
primary hepatocytes and in a panel of human non-small cell
lung carcinoma cells lines, and that loss of BOK decreases
cell growth in the latter [15, 16]. Here we demonstrate that
this is also true for HCC cells, in which loss of BOK
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resulted in reduced proliferative capacity in vitro and
in vivo. Interestingly, downregulation of BOK in HLE cells
resulted also in an increased cytoplasmic-to-nuclear BOK
ratio. It is therefore an interesting hypothesis to segregate a
role of cytoplasmic BOK in cell death regulation from a
putative role of nuclear BOK in proliferation. Importantly,
reduction of BOK by RNA interference or gene editing by
CRISPR/Cas9, resulted in induction of several genes
implicated with cell cycle arrest: BCL-2, recognized as cell
cycle regulator and able to inhibit liver carcinogenesis upon
over-expression in mice [37]; CDK5, which is essential for
neuronal cell cycle arrest and differentiation [38]; and
p19INK4d. p19INK4d was described to improve DNA repair,
decrease apoptosis and increase neuronal survival in con-
ditions of genotoxic stress [39]. Additionally, p19INK4d is
normally localized both in the nucleus and cytoplasm [40].
We conﬁrmed this cellular distribution in livers of WT
animals. Intriguingly, however, the expression of p19INK4d
in Bok-/- hepatocytes was predominantly nuclear, similar to
the distribution pattern reported for cells treated with UV
radiation [41]. We also show that p19INK4d expression was
strongly reduced in DEN-induced HCC tumor tissue of WT
mice whereas it remained detectable in tumors of Bok-/-
animals. This result is in line with a previous report showing
that p19INK4d expression is frequently lost in HCC, actually
proposing it as a new prognostic marker [42]. Like
p19INK4d, p21cip1, another cyclin kinase inhibitor with a
recognized role both in normal hepatocytes and in hepato-
carcinogenesis [43, 44], was found to be upregulated in
BOK-deﬁcient tumors. We accordingly found that loss of
the proliferative capacity in the absence of BOK depends on
p21 and p53 in HCT-116 cells. Furthermore, we identiﬁed
the previously reported NES sequence of BOK [13], which
intriguingly is located within its BH3 domain, as crucial
sequence to drive proliferation. In contrast to Bartholo-
meusz et al., however, we found that BOK with a mutated
NES accumulates in the cytoplasm rather than in the
nucleus. The underlying reason for this discrepancy is
currently not clear and warrants further investigation. Taken
together, our data indicate that BOK either requires its BH3
domain and/or a nuclear localization in order to affect cel-
lular proliferation. Interestingly, p21cip1 and p19INK4d acti-
vation may also be involved in senescence induction, which
is another well-described tumor suppressive mechanism
through which pre-malignant senescent hepatocytes are
subjected to immune cell-mediated clearance [4]. Even
though mouse leukocytes express very low levels of BOK
[15, 21], generation of a conditional Bok-deﬁcient mouse
model is necessary to address a speciﬁc role of BOK in
immune cells in DEN-induced HCC.
In summary, we show that BOK is induced by DEN and
that BOK contributes to DEN-induced hepatocellular apop-
tosis and subsequent hepatocarcinogenesis. Furthermore, loss
of BOK results in reduced proliferation of HCC cells in vitro
and in vivo, correlating with an upregulation of genes
enrolled in cell cycle arrest with a recognized role in hepa-
tocarcinogenesis. Considering this, it is reasonable to propose
that strategies aiming to prevent BOK induction or activation
during liver injury may have a favorable impact on HCC
development and progression.
Materials and methods
Reagents
IMDM, RPMI 1640 medium, and DEN were purchased
from Sigma-Aldrich (Buchs, CH). DMEM/GlutaMAX,
penicillin/streptomycin, L-glutamine, and trypsin solution
were purchased from Thermo Fisher Scientiﬁc. Fetal calf
serum (FCS, Sera Pro, ultra-low endotoxin) was purchased
from Pan Biotech (Aidenbach, DE).
Mice and treatment
Bok-/- mice were generated on a C57BL/6 inbred genetic
background as previously described [21] and were used along
with corresponding age-matched and sex-matched WT ani-
mals. All mice were maintained in pathogen-free conditions
with free access to food and water. Experiments were
approved by the Animal Experimentation Review Board of the
Canton of Bern, Switzerland (BE15/13). All mice received
humane care according to the criteria outlined in the Guide for
Care and Use of Laboratory Animals (National Institutes of
Health publications 86-23, revised 1985). For DEN-induced
HCC, DEN (25mg/kg body weight) was injected intraper-
itoneally into 14 days old males. Mice were sacriﬁced after
9 months on the standard diet (Complete Food for Mice and
Rats, No. 3432, Kliba Natag, Kaiseraugust, CH). Tumors in
each liver lobe were counted and measured with a caliper.
Tumor and non-tumor tissue was collected and quickly pro-
cessed for histological, immunochemical, and biochemical
analyses. Acute effects of DEN were studied in adult mice
injected intraperitoneally with 100mg/kg DEN and sacriﬁced
after 1, 3, and 10 days, respectively.
Alanine aminotransferase (ALT) measurement
Serum values of ALT were measured using the ALT
Enzymatic Assay according to the manufacturer’s instruc-
tions (Bioo Scientiﬁc, Austin, TX, USA).
Histology and histopathology
Freshly dissected liver samples were ﬁxed in 3.7% for-
maldehyde for 24 h, embedded in parafﬁn and 4 μm tissue
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sections stained with hematoxylin and eosin or processed
for immunohistochemistry. Histopathological evaluation
was performed blindly by a pathologist (M.M.).
Immunoblotting
Details on sample preparation and SDS-PAGE can be found
in the Online Supplementary Material. Immunoprobing was
performed with the following antibodies: mouse anti-
tubulin (B-5-1-2; Sigma-Aldrich); rabbit anti-p21 (C-19;
sc-397) and rabbit anti-CHOP (B-3) (Santa Cruz Bio-
technologies); rabbit anti-cleaved caspase-3(D175) (5A1E)
and rabbit anti-PUMA (#7467) from Cell Signaling Tech-
nology; rat anti-BIM (3C5, Enzo Life Sciences); and rabbit
anti-p19 INK4d (ab102842, Abcam). Rabbit monoclonal
anti-BOK, RabMab BOK-1-5 [15]. IRDye® 800CW and
600CW near-infrared ﬂuorochrome-conjugated secondary
antibodies were purchased from LI-COR Biotechnology
(Bad Homburg, DE). Quantitative western blot analysis was
performed using an Odyssey Fc digital imaging system
from LI-COR Biotechnology. Alternatively, horseradish
peroxidase-coupled secondary antibodies (Jackson Immu-
noResearch Europe Ltd.) were used and signals detected on
an Odyssey Fc system by enhanced chemiluminescence
(Luminata Forte, Merck Millipore). Data was quantiﬁed
using Image Studio 3.1.4 software (LI-COR).
Cytoplasmic/nuclear fractionation
Cytoplasmic and nuclear fractions were prepared according
to [45] with some modiﬁcations. Brieﬂy 3.5× 106 cells
were incubated in 0.5 ml F1 buffer (20 mM Tris pH 7.6, 50
mM β-mercaptoethanol, 0.1 mM EDTA, 2 mM MgCl2, plus
protease inhibitor cocktail) for 2 min at RT and 10 min on
ice. Fifty microliters of 10% NP-40 were added and cells
lysed by passing 3× through a 21 G needle. Lysate was
centrifuged at 600× g for 5 min at 4 °C and supernatant
collected as cytoplasmic (C) fraction. Pellet was washed 3×
in F1 buffer containing 1% NP-40 and processed as nuclear
(N) fraction.
Immunoﬂuorescence and immunohistochemistry
Immunostaining was performed after deparafﬁnization and
rehydratation through graded alcohol. Antigen retrieval was
performed in Dako Target Retrieval solution pH 6.0 (Dako,
Baar, CH) using an electric pressure cooker (2100 Retrie-
ver, Aptum, Southampton, UK). Immunoﬂuorescence was
performed with the following primary antibody incubated
overnight at 4 °C: rabbit anti-Ki-67 (SP6, Thermo Fisher
Scientiﬁc) diluted in Dako RealTM antibody diluent. Incu-
bation with Alexa Fluor 488-conjugated IgG F(ab’2) sec-
ondary antibody (Thermo Fisher Scientiﬁc) was performed
at RT for 1 h. Nuclear DNA was counterstained with Pro-
long Gold antifade reagent containing DAPI (Thermo
Fisher Scientiﬁc). Immunohistochemistry was performed
with the following primary antibodies: rabbit anti-p21 (C-
19) (sc-397, Santa Cruz Biotechnologies), and rabbit anti-
p19 INK4d (ab102842, Abcam). Staining was performed
with Dako EnvisionTM System-HRP speciﬁc for rabbit
primary antibodies following the manufacturer’s instruc-
tions. Staining was evaluated by Image-Pro Plus software
(Media Cybernetics) and the area was analyzed by the count
and size tool with hue saturation intensity (HSI) mode.
Cell death was evaluated by TUNEL staining following
the manufacturer’s instructions (In Situ Cell Death Detec-
tion Kit, Fluorescein, Roche Diagnostics). Images were
acquired using a Zeiss Observer Z.1 ﬂuorescence micro-
scope connected to a Axiocam 506 digital color camera and
using the ZEN pro 2012 (blue edition) software (Zeiss,
Feldbach, CH). The percentage of Ki-67 and TUNEL
positive cells was determined by counting at least 900
nuclei per condition.
RNA isolation and quantitative RT-PCR (qPCR)
Total RNA was extracted from liver samples with SV total
RNA isolation system (Promega, Wallisellen, CH). One
microgram of RNA was reverse-transcribed using oligo(dT)
primer and M-MLV reverse transcriptase according to the
manufacturer’s instructions (Promega). qPCR reaction was
performed using HOT FIREPol ‘EvaGreen’ qPCR Mix Plus
(Solis Biodyne, Tartu, EST) on a Real-Time PCR detection
system (CFX ConnectTM, Bio-Rad). Mouse Hprt or Gapdh
mRNA were used as reference genes. For primer sequences
see Supplementary Table S1.
Statistical analysis
Statistical analysis was performed using Prism 6 software
(GraphPad Software, Inc., La Jolla, CA, USA). Data are
presented as means ± standard deviation (SD). Unless
otherwise stated, statistical signiﬁcance was calculated
using the Student t-test or using a non-parametric
Mann–Whitney test for samples not following normal dis-
tribution with homogenous variances. P< 0.05 was con-
sidered signiﬁcant.
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